Innovative Drug Discovery Through AI at Major Conferences
Protai, an innovative AI drug discovery startup, has exciting plans to showcase its groundbreaking AIMS™ proteomics-aware-AI drug discovery platform at a series of prestigious scientific conferences. This spring, the attention will be on Protai's significant advancements in drug discovery, particularly the promising results from its preclinical KAT6A degrader program. The company's unique integration of advanced technologies positions it at the forefront of modern drug development.
Key Conference Presentations Scheduled
Protai's leadership will present at various conferences, sharing insights about their latest findings:
- HDX-MS Conference, Strasbourg, March 9-13, featuring Dr. Anjana Shenoy, Head of Proteomics
- ACS2026, Atlanta, March, with presentations by Kirill Pevzner, CTO
- TPD Summit Europe, London, March, led by Eran Seger, CEO and Kirill Pevzner, CTO
- Drug Discovery Chemistry, San Diego, April, presented by Kirill Pevzner, CTO
- AACR 2026, San Diego, April, with Eran Seger, CEO and Kirill Pevzner, CTO
Highlights of Protai's Achievements
The upcoming presentations will highlight impressive achievements and breakthroughs:
- AIMS™ Platform Validation: Protai has successfully integrated AI-driven structural modeling with mass-spectrometry-based structural proteomics. This innovative approach has supported the lead optimization of their KAT6A Targeted Protein Degradation program.
- Best-in-Class Results for PRT-001: The presentations will showcase new in vivo results from Protai's KAT6A degrader program, underscoring its potential as a leading candidate.
The Vision Behind Protai's Innovations
Eran Seger, the CEO of Protai, emphasizes the significance of combining proteomics-driven experimental evidence with advanced AI modeling. He states, "By integrating these technologies, we unveil opportunities that traditional drug discovery approaches often miss. These upcoming presentations are not just about sharing data; they're about showcasing the transformative power of AI in creating effective drug solutions for critical clinical challenges." This vision sets Protai apart in a crowded field, ensuring its innovative approach continues to garner attention.
About Protai
Protai is on a mission to transform the landscape of drug discovery through AI. By unlocking the therapeutic potential of protein complexes via structural proteomics, Protai differentiates itself from standard AI methodologies. Rather than static predictions, Protai's AIMS™ platform captures dynamic protein interactions, allowing for a more accurate modeling of protein complexes as they exist in their natural disease state. This pioneering platform is integral to the company's innovative internal drug pipeline, including a cutting-edge KAT6A degrader aimed at treating breast cancer and various solid tumors.
Contact Information
To learn more about Protai and its initiatives, please reach out to the company directly.
Frequently Asked Questions
What is the AIMS™ drug discovery platform?
The AIMS™ platform is Protai's innovative AI-driven system that integrates structural modeling and proteomics to enhance drug discovery.
What results can be expected from the KAT6A degrader program?
Protai has reported promising preclinical in vivo results, indicating significant potential for the KAT6A degrader in treating various cancers.
When are the conferences where Protai will present?
Protai will present at several conferences throughout March and April, including HDX-MS in Strasbourg and AACR 2026 in San Diego.
Who will represent Protai at these conferences?
The leadership team, including Eran Seger (CEO) and Kirill Pevzner (CTO), will present key findings.
What sets Protai apart from other drug discovery companies?
Protai's approach combines cutting-edge AI with experimental data, allowing for more dynamic and effective modeling of drug interactions.
